Browsing Category
Solution
Skin-friendly textures – by Gattefossé
Caring for patients
Patient preferences and needs as well as therapeutic indication should be considered at early stage of development of topical or transdermal formulations.
To increase adherence to skin treatments, it is important to consider patient’s needs, when designing the dosage…
Read More...
Read More...
Croda Pharma introduces new bioprocessing solutions to replace banned materials
PRESS RELEASE
10 August 2023
Croda Pharma has introduced a critical range of new bioprocessing detergents optimised for viral inactivation and cell lysis. The company’s new product range, Virodex™, offers an answer to the key market need for replacing the popular, but now banned, bioprocessing…
Read More...
Read More...
Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary delivery
Abstract
Pulmonary delivery of mRNA via inhalation is a very attractive approach for RNA-based therapy for treatment of lung diseases. In this work, we have demonstrated successful development of an mRNA-lipid nanoparticle (LNP) dry powder product (DPP), wherein the LNPs were spray dried using…
Read More...
Read More...
Use of a Platform Formulation Technology to De-Risk Solid-State Variation in Drug Development
Active pharmaceutical ingredients (APIs) can exist in multiple crystal forms, known as polymorphs, that are chemically identical. Polymorphs of an API can appear over the course of development and lead to deviations across batches affecting stability, tableting properties, flowability,…
Read More...
Read More...
How Should We Think About Pharmaceutical Excipients in Clinical Pharmacy Education?
ABSTRACT
Background: As the pharmaceutical industry shifts to a patient-oriented approach, pharmaceutical education has fairly garnered increasing attention from educators, so that the teaching course centered on pharmaceutical excipients is becoming more and more popular.
Purpose: The purpose…
Read More...
Read More...
Unlock the Potential of Poorly Soluble Drugs with Apisolex™ Technology
Don’t let poor solubility affect your innovative drug projects
Approximately 60% of potential active pharmaceutical ingredients (APIs) under development, and more than 40% of those in reformulation, are poorly water soluble1. Solubility challenges present a substantial hurdle to the development…
Read More...
Read More...
Design, development and evaluation of self-microemulsifying drug delivery system of pazopanib for…
Pazopanib is the first-line treatment for patients with advanced or metastatic renal cell carcinoma. However, the commercially available preparation is characterized by low solubility, poor bioavailability and suboptimal therapeutic concentrations in majority of patients. The aim of this study was…
Read More...
Read More...
Orally disintegrating drug carriers for paediatric pharmacotherapy
Non-compliance, dosing inaccuracy, choking risk, flavour, and instability, are some of the issues associated with paediatric, oral dosage forms — tablets, capsules, solutions, and suspensions. Orally disintegrating drug carriers, a dosage form with growing interest, are thought to overcome several…
Read More...
Read More...
COMBILOSE: A novel lactose-based co-processed excipient for direct compression
Lactose is the commonly used diluent in the manufacturing of tablets dosage form. However, the poor flowability and compressibility of lactose limit its use as a directly compressible filler binder. In this research work, composite excipient COMBILOSE was developed as a directly compressible filler…
Read More...
Read More...
Improving drug release rate, drug-polymer miscibility, printability and processability of FDM…
Slow drug release, low drug-polymer miscibility, poor printability of polymers used, and high processing temperature are major challenges in developing FDM 3D-printed tablets. These challenges were addressed in this investigation by having a model basic drug, haloperidol (mp: 151.5 °C), interact…
Read More...
Read More...